Cognition Therapeutics Inc (CGTX) concluded trading on Thursday at a closing price of $0.76, with 2.76 million shares of worth about $2.1 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -62.26% during that period and on August 22, 2024 the price saw a gain of about 1.16%. Currently the company’s common shares owned by public are about 40.13M shares, out of which, 33.79M shares are available for trading.
Stock saw a price change of 18.15% in past 5 days and over the past one month there was a price change of -58.78%. Year-to-date (YTD), CGTX shares are showing a performance of -59.00% which decreased to -45.04% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.54 but also hit the highest price of $2.95 during that period. The average intraday trading volume for Cognition Therapeutics Inc shares is 947.21K. The stock is currently trading -15.46% below its 20-day simple moving average (SMA20), while that difference is down -49.72% for SMA50 and it goes to -57.30% lower than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Cognition Therapeutics Inc (NASDAQ: CGTX) currently have 40.13M outstanding shares and institutions hold larger chunk of about 13.33% of that.
The stock has a current market capitalization of $30.44M and its 3Y-monthly beta is at 1.42. It has posted earnings per share of -$0.93 in the same period. It has Quick Ratio of 3.07 while making debt-to-equity ratio of 0.03. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CGTX, volatility over the week remained 9.66% while standing at 14.92% over the month.
Stock’s fiscal year EPS is expected to rise by 2.82% while it is estimated to increase by 3.08% in next year.
Coverage by Oppenheimer stated Cognition Therapeutics Inc (CGTX) stock as an Outperform in their note to investors on November 03, 2021, suggesting a price target of $22 for the stock.
